30-day mortality in cancer patients with atrial fibrillation and bleeding following treatment with warfarin or non-vitamin K oral antagonists
Introduction: Non-vitamin K oral antagonists (NOACs) are used to prevent thromboembolic complications in patients with atrial fibrillation (AF) due to easy administration with no need for routine monitoring compared with vitamin K antagonists (VKA). Only few treatment options are available for patients receiving NOACs with life-threatening bleeding, and the management may be further complicated in cancer patients due to interactions with the hemostatic system.
Source: Thrombosis Research - Category: Hematology Authors: A.G. Ording, K. Veres, K. Adelborg, H.T. S ørensen Tags: PO-46 Source Type: research
More News: Atrial Fibrillation | Bleeding | Cancer | Cancer & Oncology | Coumadin | Oral Cancer | Thrombosis | Vitamin K | Vitamins | Warfarin